Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis
نویسندگان
چکیده
BACKGROUND We performed a meta-analysis of cholinesterase inhibitors for patients with Lewy body disorders, such as Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. METHODS The meta-analysis included only randomized controlled trials of cholinesterase inhibitors for Lewy body disorders. RESULTS Seventeen studies (n = 1798) were assessed. Cholinesterase inhibitors significantly improved cognitive function (standardized mean difference [SMD] = -0.53], behavioral disturbances (SMD = -0.28), activities of daily living (SMD = -0.28), and global function (SMD = -0.52) compared with control treatments. Changes in motor function were not significantly different from control treatments. Furthermore, the cholinesterase inhibitor group had a higher all-cause discontinuation (risk ratio [RR] = 1.48, number needed to harm [NNH] = 14), discontinuation due to adverse events (RR = 1.59, NNH = 20), at least one adverse event (RR = 1.13, NNH = 11), nausea (RR = 2.50, NNH = 13), and tremor (RR = 2.30, NNH = 20). CONCLUSIONS Cholinesterase inhibitors appear beneficial for the treatment of Lewy body disorders without detrimental effects on motor function. However, a careful monitoring of treatment compliance and side effects is required.
منابع مشابه
Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.
This article reviews the cholinergic changes in Parkinson's disease and dementia (PDD) and dementia with Lewy bodies (DLB), their potential clinical implications, and the available evidence for cholinesterase inhibitors in the treatment of PDD and DLB. Marked neuronal loss of cholinergic nuclei, reduced cholinergic markers in the neocortex, hippocampus, and selected thalamic nuclei, and recepto...
متن کاملMEDICAL PRACTICE Lewy Body Dementia: Case Report and Discussion
Background: Lewy body dementia is a common but frequently underdiagnosed cause of dementia often mistaken for the more familiar entity of Alzheimer disease. Clinically the distinction is important, because it can have profound implications for management. Methods: The medical literature was searched using the keywords “Lewy bodies,” “Lewy body dementia,” “Alzheimer dementia,” and “parkinsonian ...
متن کاملCholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
BACKGROUND Previous Cochrane reviews have considered the use of cholinesterase inhibitors in both Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB). The clinical features of DLB and PDD have much in common and are distinguished primarily on the basis of whether or not parkinsonism precedes dementia by more than a year. Patients with both conditions have particularly se...
متن کاملCholinesterase Inhibitors from Plants: Possible Treatment Strategy for Neurological Disorders – A Review
Dementia is a chronic progressive mental disorder, which adversely affects memory, thinking, comprehension, calculation and language. Some of the most common dementias are Alzheimer’s disease, Parkinsonism, Dementia with Lewy Bodies and Myasthenia gravis. All of these disorders are related to abnormalities in the central cholinergic system, which shows a decline in acetylcholine (ACh) level due...
متن کاملTreatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
In Parkinsonian syndromes behavioural symptoms and dementia can be even more debilitating than motor symptoms and are an important predictor for nursing home placement and mortality. Neuropathologically, dementia seems to be primarily related to cortical changes rather than to subcortical alterations. Concerning neurotransmitter systems, the cholinergic system has been proposed to play a key ro...
متن کامل